Business Wire

Vincent Hayward, Co-founder of Actronika, Elected to the Academy of Sciences

15.1.2020 15:30:00 EET | Business Wire | Press release

Share

Like famous scientists before him, Vincent Hayward, co-founder of Actronika, a start-up specializing in haptics, has been invited to join the prestigious Academy of Sciences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200115005407/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vincent Hayward (Photo: Inria)

Created in 1966 by Colbert, the Academy of Sciences is made up of an assembly of scientists, chosen from among the most eminent French and foreign specialists. This showcase for French science supports research, is committed to the quality of teaching and encourages international scientific development.

Vincent Hayward, a pioneer in haptics

Winner of the 2019 Inria Grand Prize - Academy of Sciences, Vincent Hayward has already been recognized for his exceptional contribution to science with his pioneering work in haptics, the discipline that explores and exploits the sense of touch.
His interest in haptics appeared in 1991 when he was interested in the accessibility of machine interfaces to visually impaired people. The generalization of graphical interfaces effectively leaves those who are visually impaired on the sidelines. The idea was to make these interfaces accessible through hearing and touch. He developed a robot called a pantograph. This force feedback device allows you to explore the screen and touch digital objects. The quality of the results and the minimal means necessary to implement the device made for an impressive experience.
Vincent discovered a valuable subject of work and became one of the founders of an almost-unexplored research domain.
After Sorbonne - Université offered him a chair in haptics in 2007, he determined the foundations for a theory explaining how touch works.

Actronika: Results of his research

Throughout these years, his research work and his involvement in numerous national and international projects are coupled with great productivity in engineering. He designed numerous devices to stimulate the skin which will give rise to dozens of patents and the creation of the start-up Actronika.
Actronika offers haptic solutions capable of producing textures and high definition effects that can be integrated into any device: smartphones, car screens, VR accessories ... It becomes possible, for example, to materialize icons on the screen of your smartphone or create 3D buttons without bulky mechanical integration.
In the digital era, Vincent Hayward reintroduces touch and revolutionizes human-machine interactions to offer users exceptional multisensory experiences.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marina CRIFAR, Communications Manager / marina.crifar@actronika.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye